Abstract Number: 0270 • ACR Convergence 2021
Impact of Macrophage Cholesterol Loading Capacity and Interactions with Treatments on Cardiovascular Risk and Coronary Atherosclerosis Burden in Rheumatoid Arthritis
Background/Purpose: Statins and bDMARDs may decrease cardiovascular risk in RA by lowering coronary plaque formation, promoting regression and altering the composition of atherosclerotic lesions. Macrophage…Abstract Number: 0287 • ACR Convergence 2021
20 Years Follow-up of Cardiovascular Event Risk in Rheumatoid Arthritis Compared to Diabetes
Background/Purpose: Patients with rheumatoid arthritis have an increased risk for developing cardiovascular diseases (CVD) compared to the general population, similar to the CVD risk in…Abstract Number: 0461 • ACR Convergence 2021
Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria
Background/Purpose: Circulating autoantibodies like ACPA frequently develop years before symptoms of RA, during which the individual is at-risk for disease. Several lines of evidence suggest…Abstract Number: 0566 • ACR Convergence 2021
Natural Language Processing of Electronic Health Record Notes Captures Forced Vital Capacity in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Background/Purpose: Rheumatoid arthritis-interstitial lung disease (RA-ILD) has a poor long-term prognosis, including premature mortality. Longitudinal monitoring of patients in clinical and clinical trial settings includes…Abstract Number: 0589 • ACR Convergence 2021
Circulating Adipokines and Risk of Rheumatoid Arthritis in Women
Background/Purpose: Adipokines secreted by adipose tissues thought to be involved in RA pathogenesis by stimulating systematic inflammation. We examined the association between circulating adipokines (leptin,…Abstract Number: 0740 • ACR Convergence 2021
Rheumatologists’ and Patients’ Mental Models for Treatment of RA Explain Low Rates of TTT
Background/Purpose: Fewer than 50% of patients with rheumatoid arthritis (RA) are treated using a TTT strategy. The purpose of this study was to better understand…Abstract Number: L04 • ACR Convergence 2020
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
Background/Purpose: Patients (pts) with RA have increased susceptibility to seasonal influenza and its complications.1 The COVID-19 pandemic highlights the need to understand acute respiratory RNA…Abstract Number: 0032 • ACR Convergence 2020
A Prospective, Multicenter, Clinical Performance Evaluation Study for an in-vitro Diagnostics Medical Device (PREDYSTIC® Infliximab RA) for Prediction of Infliximab Responsiveness in the Treatment of Rheumatoid Arthritis
Background/Purpose: Approximately 30-40% of RA patients fail to respond to first biological therapy. Predicting the patient’s responsiveness to the first biological therapy is still an…Abstract Number: 0104 • ACR Convergence 2020
Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis
Background/Purpose: Oral JAK inhibitor, tofacitinib appeared as a new therapeutic option, beside biological therapies, which has already proven its safety and effectivity in RA, but…Abstract Number: 0149 • ACR Convergence 2020
How Stable Are Medication Necessity Beliefs and Safety Concerns in the First Year of RA?
Background/Purpose: At RA onset, DMARDs are essential to controlling inflammation and preventing disability. In people with established RA, specific beliefs about the necessity of DMARDs…Abstract Number: 0186 • ACR Convergence 2020
The Number of Associated Comorbidities Can Impact Disease Activity Scores Independently from Objective Measures of Inflammation in Patients with Rheumatoid Arthritis
Background/Purpose: Disease activity scores (DAS) are used as tools to assess persistent inflammation and need for therapeutic escalation in patients with Rheumatoid arthritis (RA). One…Abstract Number: 0202 • ACR Convergence 2020
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis
Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK)1/JAK 2 inhibitor approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in…Abstract Number: 0218 • ACR Convergence 2020
Clinical Outcomes of Earlier versus Delayed Treatment of Iraqi Patients with Rheumatoid Arthritis with Etanercept
Background/Purpose: The management of patients with early rheumatoid arthritis (RA), defined by the American College of Rheumatology (ACR) guidelines as patients who have had RA…Abstract Number: 0235 • ACR Convergence 2020
Safety and Biological Activity of Rozibafusp Alfa in Subjects with Rheumatoid Arthritis: Final Results of a Phase 1b Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study
Background/Purpose: B-cell activating factor (BAFF) and inducible costimulator ligand (ICOSL) are implicated in autoimmune disease pathogenesis, and clinical findings support their utility as drug targets…Abstract Number: 0479 • ACR Convergence 2020
Early DAS Response After DMARD-start Increases Probability of Achieving Sustained DMARD-free Remission in Rheumatoid Arthritis
Background/Purpose: Sustained DMARD-free remission (SDFR) is increasingly achievable. The pathogenesis underlying SDFR-development is unknown and patient-characteristics at diagnosis poorly explain whether SDFR will be achieved.…
- « Previous Page
- 1
- …
- 129
- 130
- 131
- 132
- 133
- …
- 188
- Next Page »